Cosmetic cross-reference

Octisalate

CAS 118-60-5

Octisalate (CAS 118-60-5) is a Phase 2 pharmaceutical compound with 2 bioactivity targets and 100 adverse event associations.

SOURCE NLM DailyMed
Label records
5
SOURCE EMBL-EBI ChEMBL
Bioactivity
2
SOURCE DrugCentral
Adverse signals
100
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Octisalate
CAS Number
118-60-5
UNII
4X49Y0596W
InChIKey
FMRHJJZUHUTGKE-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1329203
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
ETHYLHEXYL SALICYLATE
natural product
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2
Mid-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL1329203 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE NLM DailyMed 5 label rows

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

ProductIngredient Active MoietyEffective
Neutrogena Ultra Sheer Dry Touch Sunscreen Broad Spectrum SPF 70 OCTISALATE
4X49Y0596W
 OCTISALATE 20260505
SPF 50 Dry Tropix with fragrance OCTISALATE
4X49Y0596W
 ETHYLHEXYL SALICYLATE 20260505
THANKYOU FARMER Sun Project Moisture Sun OCTISALATE
4X49Y0596W
 OCTISALATE 20260505
THANKYOU FARMER Sun Project Soothing Sun OCTISALATE
4X49Y0596W
 OCTISALATE 20260505
No 7 Prime Forever SPF 50 Primer OCTISALATE
4X49Y0596W
 OCTISALATE 20260430
SOURCE EMBL-EBI ChEMBL 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 34365.13333333334 nM 3 -
- AC50 2470.3 nM 2 -
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Macular degeneration 263 821.14 10025409
Chronic sinusitis 94 250.856 10009137
Paraesthesia oral 98 228.253 10057372
Procedural pain 97 215.718 10064882
Vaginal flatulence 39 128.877 10064227
Body tinea 33 120.133 10005913
Female genital tract fistula 42 109.768 10061149
Radiculopathy 44 99.452 10037779
Proctitis 40 98.75 10036774
Infection susceptibility increased 33 95.817 10021866
Therapeutic product effect incomplete 127 93.847 10082200
Inhibitory drug interaction 33 93.292 10068071
Vaginal discharge 39 91.964 10046901
Removal of foreign body 15 87.505 10062102
Drug ineffective 461 85.805 10013709
Cardiac arrest 122 85.081 10007515
Dyspepsia 104 82.492 10013946
Anal inflammation 21 72.06 10050247
Glucose tolerance impaired 33 70.044 10018429
Poor quality sleep 47 69.63 10062519
Methaemoglobinaemia 28 67.133 10027496
Foetal death 35 66.808 10055690
SARS-CoV-2 test negative 18 60.746 10084273
Impaired quality of life 37 59.409 10076936
Local anaesthetic systemic toxicity 17 58.808 10082534
Bone density decreased 34 55.245 10049470
Purpura 36 53.56 10037549
Appendicolith 25 49.999 10074458
Product packaging confusion 15 48.449 10074776
Oral candidiasis 41 48.432 10030963
Hyperlipidaemia 40 47.921 10062060
Impaired work ability 35 47.324 10052302
Colitis ulcerative 44 46.034 10009900
Pyrexia 242 46.026 10037660
Constipation 139 44.833 10010774
Ventricular fibrillation 39 44.197 10047290
Anaphylactic shock 41 43.84 10002199
Tracheal deviation 9 43.007 10044287
Frequent bowel movements 39 42.623 10017367
Foreign body 17 42.363 10070245
Oral herpes 36 39.41 10067152
Proctalgia 24 39.395 10036772
Skin disorder 40 38.266 10040831
Cardiogenic shock 40 37.89 10007625
Phrenic nerve paralysis 9 37.044 10064964
Foreign body in respiratory tract 10 36.823 10079847
Accident 22 35.826 10000369
Appendicitis 28 33.15 10003011
Rheumatoid arthritis 5 30.888 10039073
Chemical burn 9 29.233 10008420

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
OCTISALATE 91327 SU MTHSPL
Octisalate 91327 SU MTHSPL
octisalate 91327 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Octisalate used for in pharmaceutical contexts?

Octisalate (CAS 118-60-5) appears in DailyMed active-ingredient label rows, including Neutrogena Ultra Sheer Dry Touch Sunscreen Broad Spectrum SPF 70, SPF 50 Dry Tropix with fragrance, THANKYOU FARMER Sun Project Moisture Sun.

What are the known adverse events for Octisalate?

Octisalate has 100 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Macular degeneration, Chronic sinusitis, Paraesthesia oral, Procedural pain, Vaginal flatulence. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Octisalate also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Ethylhexyl Salicylate with EU status "permitted".

What clinical phase is Octisalate in?

Octisalate is rendered with ChEMBL max phase 2.